26
Participants
Start Date
December 31, 2025
Primary Completion Date
April 30, 2026
Study Completion Date
May 31, 2026
OPT101
OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
Placebo
0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
Denver Health and Hospital Authority, Denver
Op-T LLC
INDUSTRY